Reference is made to the stock exchange notice published on 11 September 2018 regarding completion of a subsequent offering with gross proceeds of approximately NOK 14.9 million (the "Subsequent Offering").

 

In the Subsequent Offering, the Company has issued 6,600,298 new shares, implying a share capital increase of NOK 6,600,298. The share capital increase pertaining to the Subsequent Offering has now been registered with the Norwegian Register of Business Enterprises. The new share capital of the Company is NOK 294,836,829 divided by 294,836,829 shares, each with a par value of NOK 1.

 

The new shares will be delivered to the investors in the Subsequent Offering and admitted to trading on Oslo Axess as soon as practically possible.

 

For further information, please contact:

Jon Olav Ødegård, CFO of Hofseth BioCare ASA

Mob: +47 936 32 966

E-mail:joo@hofsethbiocare.no

 

About Hofseth BioCare ASA:

HBC is a Norwegian biotech company that offers high-value ingredients and finished products for humans and pets. The company is founded on the core values of sustainability, traceability and optimal utilization of natural resources. Through an innovative hydrolysis technology, HBC is able to preserve the quality of salmon oil, proteins and calcium, prepared of fresh salmon off-cuts. HBC's objective is to contribute to the efficient use of marine resources and deliver quality products for ingredients and finished consumer products in the nutrition market.

Hofseth BioCare's headquarters are located in Ålesund, Norway with branches in Oslo, Chicago, Palo Alto, Mumbai and Tokyo. HBC is listed on Oslo Stock Exchange Axess list with ticker "HBC".

More information about Hofseth BioCare at www.hofsethbiocare.com and www.facebook.com/hofsethbiocare

 

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.